First-Line Herceptin® Monotherapy in Metastatic Breast Cancer

  title={First-Line Herceptin{\textregistered} Monotherapy in Metastatic Breast Cancer},
  author={Charles L. Vogel and Melody A. Cobleigh and Debu Tripathy and John C. Gutheil and Lyndsay N. Harris and Louis Fehrenbacher and Dennis J. Slamon and Maureen Murphy and William F. Novotny and Michael Burchmore and Steven Shak and Stanford J. Stewart},
  pages={37 - 42}
The pivotal phase II and III Herceptin® trials proved the efficacy and safety of second- or third-line single-agent Herceptin and first-line Herceptin in combination with chemotherapy, respectively. In the current trial, 114 patients were randomized to one of two dose groups of first-line Herceptin monotherapy: standard dose of 4 mg/ kg initial dose followed by 2 mg/kg intravenous (i.v.) weekly; or high dose of 8 mg/kg initial dose followed by 4 mg/kg i.v. weekly. The regimen was generally well… 

Figures and Tables from this paper

Efficacy and safety of combined trastuzumab and paclitaxel therapy as a second-line treatment in women with metastatic Breast Cancer: A single institutional experience

Combined trastuzumab and paclitaxel therapy, administered as second-line or later treatment, produced lasting objective responses and was well tolerated by women with HER-2 overexpressing metastatic breast cancer.

Trastuzumab and interleukin-2 in HER2-positive metastatic breast cancer: a pilot study.

Test whether interleukin (IL)-2, by increasing FcRgammaIII(+) natural killer cell numbers and cytolytic function in vivo, when added to trastuzumab, can increase efficacy, be safely given, and avoid the use of chemotherapy is performed.

Ixabepilone as Monotherapy or in Combination with Capecitabine for the Treatment of Advanced Breast Cancer

Ixabepilone as single agent appears to show excellent antitumor activity in patients with TNBC MBC and depending on prior exposure to chemotherapy both single agent IxabEPilone or in combination with Capecitabine can be used safely and effectively for treatment of advanced breast cancer.

A case of metastatic Breast Cancer with HER2 gene amplification that responded completely to single agent trastuzumab

An 80-year-old woman visited the authors' hospital with a massive ulcerated tumor in the upper lateral quadrant of the right breast and her performance status improved to zero, and she is alive and free from the disease 24 months after the disappearance of the tumor.

An open-label, randomized phase II study of adecatumumab, a fully human anti-EpCAM antibody, as monotherapy in patients with metastatic breast cancer.

Investigation of two doses of the fully human IgG1 anti-EpCAM antibody adecatumumab in patients with metastatic breast cancer shows dose- and target-dependent clinical activity in EpCAM-positive MBC, albeit no objective tumor regression.

Prolonged Survival of Patients Receiving Trastuzumab beyond Disease Progression for HER2 Overexpressing Metastatic Breast Cancer (MBC)

Compared to historical controls, overall survival appears to be markedly prolonged, particularly in patients who received sequential trastuzumab-based treatment beyond disease progression.

Trastuzumab-containing regimens for metastatic breast cancer.

The evidence on the efficacy and safety of therapy with trastuzumab (overall) and in relation to the type of co-administered regimen and the line of treatment, i.e. first-line or beyond progression, in women with HER2-positive metastatic breast cancer was assessed.

Trastuzumab (Herceptin®): Monoclonal Antibody in the Treatment of HER2/neu-Overexpressing Breast Cancer in the Metastatic and (Neo)adjuvant Situation

The combination of trastuzumab and paclitaxel showed an improvement of all clinical parameters, including overall survival, for the first time in the history of palliative breast cancer therapy.

Trastuzumab containing regimens for early breast cancer.

Trastuzumab significantly improves OS and DFS in HER2-positive women with early and locally advanced breast cancer, although it also significantly increases the risk of CHF and LVEF decline.



Herceptin® Alone or in Combination with Chemotherapy in the Treatment of HER2-Positive Metastatic Breast Cancer: Pivotal Trials

Large pivotal phase II and III clinical trials investigated the therapeutic efficacy and safety of the humanized anti-HER2 monoclonal antibody, Herceptin®, alone and in combination with standard

Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment.

  • M. PegramA. Lipton D. Slamon
  • Medicine, Biology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 1998
The use of rhuMAb HER2 in combination with CDDP in patients with HER2/neu-overexpressing metastatic breast cancer results in objective clinical response rates higher than those reported previously for CDDP alone, or rhu MAb Her2 alone.

Retrospective Analysis of the Safety of Herceptin® Immunotherapy in Metastatic Breast Cancer

Although the benefit to risk ratio of Herceptin remains favorable, physicians must be vigilant and aggressive in managing cardiotoxicity and infusion-related reactions.

Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease.

  • M. CobleighC. Vogel D. Slamon
  • Medicine, Biology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 1999
Recombinant humanized anti-HER2 monoclonal antibody, administered as a single agent, produces durable objective responses and is well tolerated by women with HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease.

Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer.

  • J. BaselgaD. Tripathy L. Norton
  • Medicine, Biology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 1996
RhuMAb HER2 is well tolerated and clinically active in patients with HER2-overexpressing metastatic breast cancers that had received extensive prior therapy and justifies further evaluation of this agent.

Overview of the trastuzumab (Herceptin) anti-HER2 monoclonal antibody clinical program in HER2-overexpressing metastatic breast cancer. Herceptin Multinational Investigator Study Group.

  • S. Shak
  • Biology, Medicine
    Seminars in oncology
  • 1999
The data suggest that trastuzumab will be an important new treatment option for women with HER2-overexpressing metastatic breast cancer.


Trastuzumab increases the clinical benefit of first-line chemotherapy in metastatic breast cancer that overexpresses HER2 and potentially severe and, in some cases, life-threatening, the symptoms generally improved with standard medical management.

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

The addition of trastuzumab to chemotherapy was associated with a longer time to disease progression, a higher rate of objective response, a longer duration of response, and a lower rate of death at 1 year.

Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers

The synergistic interaction of rhuMAb HER2 with alkylating agents, platinum analogs and topoisomerase II inhibitors, as well as the additive interaction with taxanes, anthracyclines and some antimetabolites in HER-2/neu-overexpressing breast cancer cells demonstrates that these are rational combinations to test in human clinical trials.

Cardiotoxicity in patients receiving transtuzumab (Herceptin): primary toxicity, synergistic or sequential stress, or surveillance artifact?

In early clinical studies with trastuzumab, cardiomyopathy was observed with a clinical expression similar to that seen with the anthracyclines (ie, a potentially progressive decrease in cardiac systolic function).